**"APPROVED"**

**State Health Insurance Fund**

**Executive Director**

**\_\_\_\_\_\_\_\_\_\_\_\_ Z.Sh.Ermatov**

**"\_\_\_\_" \_\_\_\_\_\_\_\_\_\_\_\_ 2024 year**

**Terms of reference and conditions**

|  |  |  |
| --- | --- | --- |
| 1 | Customer: | State Health Insurance Fund |
| 2 | Contents of selection | Selection of the best proposals for determining the marginal cost of reimbursement of medicines (in terms of the form of release, dose, and international nonproprietary name (INN) provided based on the reimbursement program |
| 3 | Selection type | Selecting the best offer |
| 4 | Source for downloading the selection documentation | https://dtsj.uz/uz/reimbursatsiya/ |
| 5 | Documents submitted for participation in the selection | 1. Provision of a certificate of conformity for each medicinal product according to INN, trade name, form of release and dosage (Appendix #1)  2. Submission of a competitive price offer for each medicinal product according to INN, trade name, form of release, and dosage (Appendix #2).  In this case, the competitive price offer should not exceed the reference price for this medicinal product according to INN, trade name, form of release, and dosage.  3. Provision of a letter of guarantee on prevention of corruption risks. |
| 6 | Time and address of receiving bids | Competitive price offers are provided by e-mail ([reimbursement@dtsj.uz](mailto:reimbursement@dtsj.uz)) within 10 (ten) business days from the date this announcement is posted for each medicinal product in the context of INN, trade name, form of release, and dosage. |
| 7 | The procedure and deadline for evaluating bids | 1. Competitive price proposals will be reviewed within 5 (five) business days after the deadline for submitting competitive proposals at a meeting of the Commission formed under the State Health Insurance Fund.  2. Based on competitive price proposals, a list of prices is formed in ascending order by INN, trade names, forms of release, and dosages. Then, starting from the lowest price index, 5 (five) medicines are selected by trade name, form of release, and dosage.  3. Based on the proposed price, the maximum cost of reimbursement is set for the trade name, form, and dose of the selected medicines. At the same time, the proposed price, retail trade allowance, and VAT are taken into account as part of the marginal cost of reimbursement.  4. The highest marginal cost of reimbursement among the selected medicines is taken as the highest marginal cost of reimbursement for INN, form, and dose of this medicinal product.  5. Suppliers who have submitted their proposals to the State Medical Insurance Fund are notified of the accepted marginal cost of reimbursement for INN, form, and dose of the corresponding drug through the State Health Insurance Fund's website (https://dtsj.uz/ru/reimbursatsiya).  Suppliers who have offered prices exceeding the maximum cost of compensation are allowed to change the prices indicated in their offer to prices not exceeding the maximum cost of compensation, and within 48 hours to submit updated offers by the established procedure to the e-mail of the State Medical Insurance Fund. ([reimbursement@dtsj.uz](mailto:reimbursement@dtsj.uz)).  6. The Commission shall consider the updated proposals within 2 (two) working days and, together with the preliminary meeting results, approve the list of medicines with an appropriate protocol indicating the trade name, form, and dose of medicines and the marginal cost of reimbursement for each INN, form, and dose of medicines.  7. The minutes of the Commission's meeting and the approved list of trade names, forms, and dosages of medicines, as well as the maximum cost of reimbursement, are published on the website of the State Health Insurance Fund (https://dtsj.uz/ru/reimbursatsiya /) and social media pages on the next business day after signing this protocol. |

**APPENDIX #1**

**List of medicines provided based on the reimbursement program by dosage form and volume**

|  |  |  |  |
| --- | --- | --- | --- |
| **Т/р** | **International nonproprietary name** | **Dosage form** | **Volume (pcs.)** |
| **I. Drugs used to treat pathologies of the gastrointestinal tract Proton Pump Inhibitors** | | | |
| **Proton Pump Inhibitors** | | | |
| 1 | Omeprazole | 10 mg capsule | 494231 |
| Omeprazole | 10 mg capsule | 4971286 |
| Omeprazole | 10 mg capsule | 1662530 |
| **H2 blockers** | | | |
| **II. Drugs that affect peripheral adrenergic processes** | | | |
| ***Drugs used for anti-asthmatic and chronic obstructive pulmonary disease*** | | | |
| 2 | Salbutamol | aerosol 100 mcg/dose 7 g 200 dose | 675355 |
| **III. Drugs used to treat pathologies of the endocrine system** | | | |
| ***Iodine preparations*** | | | |
| 3 | Potassium iodide | 200 mcg tablet | 6258827 |
| ***Antithyroid drugs*** | | | |
| 4 | Thiamazole | 5 mg tablet | 159869 |
| ***Thyroid hormones*** | | | |
| 5 | Levothyroxine sodium | tablet of 100 mcg | 443613 |
| ***Thyroid hormones*** | | | |
| 6 | Desmopressin 100 mcg | nasal drops 100 mcg/ml 5 ml | 162875 |
| metered nasal spray 10 mcg/ dose 5 ml | 71016 |
| **Expectorant agents** | | | |
| 7 | Ambroxol | 30 mg tablet | 1650797 |
| **Medicines that affect the cardiovascular system** | | | |
| **Antiarrhythmic drugs** | | | |
| 8 | Verapamil | tablet 80 mg | 158756 |
| **Antianginal drugs** | | | |
| 9 | Isosorbide dinitrate | spray 1.25 mcg/dose 15 ml 300 dose | 39272 |
| tablet 10 mg | 501893 |
| 10 | Isosorbite mononitrate | 20 mg tablet | 265881 |
| Isosorbite mononitrate | 40 mg tablet | 261115 |
| Isosorbite mononitrate | capsule 20 mg | 240357 |
| Isosorbite mononitrate | capsule 40 mg | 228554 |
| ***Antiplatelet agents*** | | | |
| 11 | Acetylsalicylic acid | tablet 50 mg | 391747 |
| Acetylsalicylic acid | tablet 75 mg | 392213 |
| Acetylsalicylic acid | tablet 100 mg | 912040 |
| Acetylsalicylic acid | tablet 150 mg | 511133 |
| 12 | Clopidogrel | tablet 75 mg | 5552213 |
| **Selective (cardioselective) β1−adrenoblockers** | | | |
| 13 | Bisoprolol | tablet 2,5 mg | 783507 |
| Bisoprolol | tablet 5 mg | 3815619 |
| Bisoprolol | tablet 10 mg | 1365107 |
| **Calcium Channel Blockers** | | | |
| 14 | Amlodipine | tablet 5 mg | 4398508 |
| Amlodipine | tablet 10 mg | 3722146 |
| **Angiotensin converting enzyme inhibitors** | | | |
| 15 | Enalapril maleat | tablet 5 mg | 8939816 |
| Enalapril maleat | tablet 10 mg | 12661204 |
| **Hypolipidemic agents** | | | |
| 16 | Atorvastatin | tablet 10 mg | 3441903 |
| Atorvastatin | tablet 20 mg | 5102783 |
| Atorvastatin | tablet 40 mg | 1516689 |
| Atorvastatin | tablet 80 mg | 945818 |
| **Agents that affect platelet aggregation and blood clotting** | | | |
| 17 | Warfarin | tablet 2,5 mg | 6095587 |
| Warfarin | tablet 3 mg | 6087808 |
| Warfarin | tablet 5 mg | 546490 |
| **Diuretic and antidiuretic agents** | | | |
| 18 | Spironolactone | tablet 2,5 mg | 1699006 |
| Spironolactone | tablet 50 mg | 1527704 |
| Spironolactone | tablet 100 mg | 838664 |
| 19 | Furosemide | tablet 40 mg | 1586081 |
| **Drugs used to treat pathologies of the endocrine system** | | | |
| **Anti-diabetes drugs** | | | |
| 20 | Gliclazide | tablet 30 mg | 3951809 |
| Gliclazide | tablet 60 mg | 3826385 |
| 21 | Metformin | tablet 500 mg | 9403927 |
| Metformin | tablet 850 mg | 6764612 |
| Metformin | tablet 1000 mg | 5964768 |
| 22 | Empagliflozin | tablet 10 mg | 1448111 |
| Empagliflozin | tablet 25 mg | 1359987 |
| **Hormones of the bark part of the adrenal gland, glucocorticoids** | | | |
| 23 | Prednisone | tablet 5 mg | 1151701 |
| **IX. Vitamins and their derivatives** | | | |
| 24 | Folic acid | tablet 1 mg | 1431055 |
| Folic acid | tablet 5 mg | 1243595 |
| **Drugs that stimulate erythropoiesis** | | | |
| 25 | Preparations of divalent Fe (II) | tablet 100 mg | 3456197 |
| Preparations of divalent Fe (II) | capsule 100 mg | 2787188 |
| 26 | Trivalent Fe (III) preparation | tablet 100 mg | 4717591 |
| Trivalent Fe (III) preparation | capsule 100 mg | 4390200 |
| **Anthelmintic agents** | | | |
| 27 | Albendazole | tablet | 1763153 |
| Albendazole | capsule | 281676 |

**APPENDIX #2**

**Submission of competitive proposals**

*date*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **#** | **INN** | **Trade name** | **Dosage** | **Price** |
| 1 |  |  |  |  |
| 2 |  |  |  |  |
| ... |  |  |  |  |

date

Note: *Name of the organization \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Full name of the supervisor*

*seal (signature)*

*The proposals must be signed and scanned (PDF file) and submitted with an Excel file*